Jiang XL, Samant S, Lesko LJ, Schmidt S. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015;54(2):147–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Terpening C. Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol. 2010;4:117–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akkaif MA, Daud NAA, Sha’aban A, Ng ML, Abdul Kader MAS, Noor DAM, et al. The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD). Molecules. 2021;26(7).

Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80(5):486–501.

Article  CAS  PubMed  Google Scholar 

Polasek TM, Doogue MP, Miners JO. Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Ther Adv drug Saf. 2011;2(6):253–61.

Article  PubMed  PubMed Central  Google Scholar 

Garcia AE, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP. Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis. PLoS ONE. 2011;6(10): e26035.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Hear J Cardiovasc Pharmacother. 2020;6(4):203–10.

Article  Google Scholar 

Seelig A. P-Glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers. Front Oncol. 2020;10:1–16.

Article  Google Scholar 

Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom Proteom Bioinf. 2016;14(5):298–313.

Article  CAS  Google Scholar 

Mirzaev KB, Rytkin E, Ryzhikova KA, Grishina EA, Sozaeva ZA, Fedorinov DS, et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metab Pers Ther. 2018;33(3):109–18.

Article  CAS  PubMed  Google Scholar 

Brown SA, Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. J Pers Med. 2018;8(1).

Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schömig A, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010;160(3):506–12.

Article  CAS  PubMed  Google Scholar 

Mitra S, Khurana P, Panmei T, Kshatriya GK. Allele frequencies of PON1 Q192R polymorphism in four populations of India. Environ Toxicol Pharmacol. 2015;39(3):1051–6.

Article  CAS  PubMed  Google Scholar 

Otocka-Kmiecik A. Effect of carotenoids on paraoxonase-1 activity and gene expression. Nutrients. 2022;14(14).

Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect. 2003;111(11):1403–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Wang H, Xuan L, Shi X, Zhou T, Zhang N, et al. Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. Medicine. 2017;96(14): e6553.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Mahayri ZN, Patrinos GP, Wattanapokayakit S, Iemwimangsa N, Fukunaga K, Mushiroda T, et al. Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations. Sci Rep. 2020;10(1):1–15. https://doi.org/10.1038/s41598-020-78231-3.

Article  CAS  Google Scholar 

Jarrar Y, Lee SJ. Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates. vol. 12, Journal of personalized medicine. Switzerland; 2022.

Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959–67.

Article  CAS  PubMed  Google Scholar 

Pan X, Huang L, Li M, Mo D, Liang Y, Liu Z, et al. The association between PON1 (Q192R and L55M) gene polymorphisms and risk of cancer: a meta-analysis based on 43 studies. Biomed Res Int. 2019;2019:5897505.

Article  PubMed  PubMed Central  Google Scholar 

Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagnost. 2018;20(3):269–76. https://doi.org/10.1016/j.jmoldx.2018.01.011.

Article  CAS  Google Scholar 

Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agúndez JAG, et al. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021;109(2):352–66.

Article  PubMed  Google Scholar 

Dean L. Carisoprodol therapy and CYP2C19 genotype. Med Genet Summ. 2012;(MD):1–19.

Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Al-Maskari F. Stakeholders’ interest and attitudes toward genomic medicine and pharmacogenomics implementation in the United Arab Emirates: a qualitative study. Public Health Genom. 2021;24(3–4):99–109.

Article  Google Scholar 

Al-Mahayri ZN, Khasawneh LQ, Alqasrawi MN, Altoum SM, Jamil G, Badawi S, et al. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. Hum Genomics. 2022;16(1):1–12.

Article  Google Scholar 

Rahma AT, Ali BR, Patrinos GP, Ahmed LA, Elbarazi I, Abdullahi AS, et al. Knowledge, attitudes, and perceptions of the multi-ethnic population of the United Arab Emirates on genomic medicine and genetic testing. Hum Genom. 2023;17(1):63.

Article  Google Scholar 

Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Elsheik M, et al. Development of the pharmacogenomics and genomics literacy framework for pharmacists. Hum Genomics. 2021;15(1):62

Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Al Maskari F. Genomics and pharmacogenomics knowledge, attitude and practice of pharmacists working in United Arab Emirates: findings from focus group discussions-a qualitative study. J Pers Med. 2020;10(3).

Fahim SM, Alexander CSW, Qian J, Ngorsuraches S, Hohmann NS, Lloyd KB, et al. Current published evidence on barriers and proposed strategies for genetic testing implementation in health care settings: a scoping review. J Am Pharm Assoc. 2023;63(4):998–1016.

Article  Google Scholar 

Koufaki MI, Fragoulakis V, Díaz-Villamarín X, Karamperis K, Vozikis A, Swen JJ, et al. Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study. Hum Genom. 2023;17(1):51. https://doi.org/10.1186/s40246-023-00495-3.

Article  Google Scholar 

Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189–99. https://doi.org/10.1067/mcp.2001.117412.

Article  CAS  PubMed  Google Scholar 

Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13(8):481–94.

Article  CAS  PubMed  Google Scholar 

Tang K, Ngoi SM, Gwee PC, Chua JMZ, Lee EJD, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12(6):437–50.

Article  CAS  PubMed  Google Scholar 

Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics. 2011;12(5):713–25.

Article  CAS  PubMed  Google Scholar 

Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon T, et al. Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial. JAMA Neurol. 2019;76(5):552–60. https://doi.org/10.1001/jamaneurol.2018.4775.

Article  PubMed  PubMed Central  Google Scholar 

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75. https://doi.org/10.1056/NEJMoa0808227.

Article  CAS  PubMed  Google Scholar 

Rjoub M, Saleh A, Hakooz N, Imraish A, Jarrar Y, Zihlif M. CYP2C19 * 17 among Jordanian patients taking clopidogrel. 2018;17:2275–80.

Alharbi KK, Alnbaheen MS, Alharbi FK, Hasanato RM, Khan IA. Q192R polymorphism in the PON1 gene and familial hypercholesterolemia in a Saudi population. Ann Saudi Med. 2017;37(6):425–32.

Article  PubMed  PubMed Central  Google Scholar 

Janicsek I, Sipeky C, Bene J, Duga B, et al. Erratum to: Significant interethnic differences in functional variants of PON1 and P2RY12 genes in Roma and Hungarian population samples. Mol Biol Rep. 2014.

Sunay SZ, Kayaaltı Z, Bayrak T, Söylemezoğlu T. Effect of paraoxonase 1 192 Q/R polymorphism on paraoxonase and acetylcholinesterase enzyme activities in a Turkish population exposed to organophosphate. Toxicol Ind Health. 2013;31(12):1061–8. https://doi.org/10.1177/0748233713487246.

Article  CAS  PubMed  Google Scholar 

Janicsek I, Sipeky C, Bene J, Duga B, Melegh B, Sümegi K, et al. Significant interethnic differencies in functional variants of PON1 and P2RY12 genes in Roma and Hungarian population samples. Mol Biol Rep. 2015;42(1):227–32.

Article  CAS  PubMed  Google Scholar 

Corredor-Orlandelli D, Sambracos-Parrado S, Mantilla-García S, Tovar-Tirado J, Vega-Ramírez V, Mendoza-Ayús SD, et al. Association between paraoxonase-1 p.Q192R polymorphism and coronary artery disease susceptibility in the Colombian population. Vasc Health Risk Manag. 2021;17:689–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang YJ, Li DJ, Li ZY, Hu XL, Li H, Ma QL, et al. Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease. BMC Cardiovasc Disord. 2022;22(1):1–11.

Article